Developer docs
API playgroundTry for free, no card

Search company profiles

ChromaCode

Full company profile

uuid0000nf8

Namestring
ChromaCode
Legal namestring
ChromaCode, Inc.
Websiteurl
chromacode.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

ChromaCode is a privately held molecular diagnostics company founded in 2012 and headquartered in Carlsbad, California. The company has developed HDPCR™ (High-Definition PCR), a proprietary multiplexing chemistry that uses amplitude modulation and multi-spectral encoding with standard TaqMan probes and commercial enzymes to deliver greater than 4X the multiplexing capacity of conventional digital PCR. The platform is paired with ChromaCode Cloud™, a HIPAA, HITRUST, ISO 13485, and GDPR compliant SaaS application that automates decoding of PCR signal data and produces comprehensive multi-analyte results in minutes without requiring laboratory hardware or software installation.

ChromaCode's primary customer segment is clinical and molecular diagnostic laboratories performing oncology and genomic testing, with secondary customers in pharmaceutical companies seeking customizable assays for companion diagnostics and clinical trial support. The company generates revenue through the sale of proprietary HDPCR reagent kits combined with subscriptions to ChromaCode Cloud software, sold direct via a sales-led motion. The instrument-agnostic architecture allows adoption on existing real-time and digital PCR instruments, enabling decentralized distribution into community labs for repeat-testing applications such as treatment monitoring and transplant rejection surveillance. Named reference customers include the University of Minnesota Medical School, and the company has cited market opportunities of 1.9M US patients annually for tumor profiling, 3.3M-6.7M for MRD, and 1.6M US tests for transplant rejection monitoring.

The company has raised approximately $97.8M across disclosed funding rounds since 2017, including a $37.97M round in 2022 and a strategic corporate investment from Global Brain's Shimadzu Future Innovation Fund in June 2023. ChromaCode operates with 51-100 employees and is pursuing product extensions into Minimal Residual Disease (MRD) testing and disease monitoring, both currently labeled as in development on the company's website.

Short descriptiontext

ChromaCode is a molecular diagnostics company that develops HDPCR™ multiplexing chemistry and ChromaCode Cloud™ SaaS, enabling clinical laboratories and pharmaceutical companies to perform NGS-quality multi-analyte oncology and genomic testing on existing PCR instruments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, PCR multiplexing, clinical bioinformatics, oncology genomics, reagent kits
Industry4 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1HDPCR Reagent Kits
TypeHardware Sales
Description

Sale of proprietary HDPCR reagent kits for molecular profiling applications. The company enables ≥80% margins for lab partners through low cost of goods sold and higher throughput compared to conventional dPCR.

chromacode.com
2ChromaCode Cloud Software Subscription
TypeSubscription Recurring
Description

Cloud-based software-as-a-service for data analysis and interpretation. ChromaCode Cloud provides automated decoding and comprehensive results with secure, HIPAA and HITRUST compliant data handling. Account setup in minutes with no installation required.

chromacode.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Reagent kits and ChromaCode Cloud software - contact for pricing
ModelOtherBilling cadenceMonthly
Notes

No public pricing listed. Customers contact company directly for reagent kit and software pricing.

chromacode.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

ChromaCode sells proprietary HDPCR™ (High-Definition PCR) reagent kits paired with the ChromaCode Cloud™ SaaS software platform to clinical laboratories and pharmaceutical companies. The HDPCR chemistry enables high-level multiplexing of DNA and RNA biomarkers using standard TaqMan probes and commercial PCR instruments, while ChromaCode Cloud automatically decodes the PCR signal data to deliver comprehensive multi-analyte results in minutes without requiring hardware or software installation. The integrated platform supports tumor profiling, minimal residual disease (MRD) testing, and disease monitoring applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • >4X multiplexing vs conventional dPCR
+4 more records
Product overview1 text field

ChromaCode offers a genomics multiplexing platform consisting of two integrated components: HDPCR™ (High-Definition PCR) technology and ChromaCode Cloud™ software. HDPCR is the core chemistry platform that enables high-multiplexing PCR testing using standard instruments, TaqMan probes, and commercial enzymes. ChromaCode Cloud is the companion SaaS platform that automates data analysis, providing signal decoding and target identification for results generation. The platform is instrument-agnostic and supports standard real-time and digital PCR instrument output files.

Product and service2 records
1HDPCR™ (High-Definition PCR) Reagent Kits
CategoryMolecular Diagnostics Reagents
Description

Proprietary multiplexing PCR reagent kits that use amplitude modulation and multi-spectral encoding with standard TaqMan probes and commercial enzymes to enable >4X multiplexing compared to conventional digital PCR. Sold to clinical laboratories and pharmaceutical companies for tumor profiling, MRD testing, and disease monitoring applications.

2ChromaCode Cloud™
CategoryClinical Bioinformatics Software
Description

Cloud-based SaaS platform that automates decoding of PCR signal data from HDPCR assays, providing comprehensive multi-analyte results in minutes without requiring hardware or software installation. Supports most standard real-time and digital PCR instrument output files and is HIPAA, HITRUST, ISO 13485, and GDPR compliant. Sold to clinical laboratories alongside HDPCR reagent kits.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bio-Rad's QX200 Droplet Digital PCR and related real-time/digital PCR reagent lines compete directly with ChromaCode's HDPCR multiplexing chemistry for clinical lab oncology and genomics applications. Both companies target the same workflow gap between PCR and NGS.

TypeBroad incumbent
Description

QIAGEN is a broad molecular diagnostics incumbent offering sample-prep to interpretation workflows used by the same clinical lab customers ChromaCode serves. Its QIAcuity digital PCR platform and oncology sample-to-insight portfolio directly overlap HDPCR's positioning as a PCR-to-NGS bridging solution.

TypeDirect peer
Description

Natera's Signatera tumor-informed MRD test competes head-on with ChromaCode's HDPCR MRD pipeline, both targeting the same 3.3M+ US patient MRD opportunity. They compete for the same oncology monitoring recurring-revenue economics ChromaCode is positioning HDPCR to disrupt at lower cost.

TypeDirect peer
Description

Adaptive's clonoSEQ is the dominant NGS-based MRD test for hematologic malignancies, competing directly with ChromaCode's HDPCR MRD development pipeline. Both target the same cancer monitoring use case where ChromaCode claims comparable NGS sensitivity at lower cost.

TypeDirect peer
Description

Guardant's liquid biopsy and tumor profiling products (Guardant360, Reveal MRD) compete in the same oncology biomarker panel market that HDPCR targets, though using NGS-based approaches. They overlap on customer base (clinical labs and oncologists) and use case (comprehensive genomic profiling).

TypeDirect peer
Description

Personalis's NeXT Personal and related tumor profiling/MRD offerings compete directly with ChromaCode's HDPCR oncology menu. Both target biopharma companion Dx and clinical oncology customers seeking comprehensive genomic profiling and minimal residual disease monitoring.

TypeDirect peer
Description

Standard BioTools' Biomark HD and Juno systems, plus Advanta dPCR assays, are direct multiplexing PCR competitors to HDPCR. They serve the same oncology and immunology research and clinical lab customers seeking high-content PCR panels.

TypeBroad incumbent
Description

NeoGenomics operates clinical oncology laboratories offering comprehensive tumor profiling and MRD testing, overlapping ChromaCode's end-customer base and use cases. While a service provider rather than a platform vendor, it represents the incumbent lab workflow ChromaCode's decentralized kit model aims to displace.

TypeBroad incumbent
Description

Exact Sciences (Cologuard, Oncotype, Previon) operates in molecular diagnostics with growing oncology MRD and tumor profiling ambitions that overlap ChromaCode's stated roadmap. It represents a broad incumbent with the commercial scale and reimbursement leverage ChromaCode would need to compete with at full scale.

TypeEmerging player
Description

Stilla's naica digital PCR system is an emerging multiplexing dPCR platform competing in the same oncology and liquid biopsy use cases as HDPCR. Both companies target labs seeking higher multiplexing than conventional dPCR at lower complexity than NGS.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChromaCode

Molecular Diagnosticschromacode.com

ChromaCode is a molecular diagnostics company that develops HDPCR™ multiplexing chemistry and ChromaCode Cloud™ SaaS, enabling clinical laboratories and pharmaceutical companies to perform NGS-quality multi-analyte oncology and genomic testing on existing PCR instruments.

What ChromaCode does

ChromaCode is a privately held molecular diagnostics company founded in 2012 and headquartered in Carlsbad, California. The company has developed HDPCR™ (High-Definition PCR), a proprietary multiplexing chemistry that uses amplitude modulation and multi-spectral encoding with standard TaqMan probes and commercial enzymes to deliver greater than 4X the multiplexing capacity of conventional digital PCR. The platform is paired with ChromaCode Cloud™, a HIPAA, HITRUST, ISO 13485, and GDPR compliant SaaS application that automates decoding of PCR signal data and produces comprehensive multi-analyte results in minutes without requiring laboratory hardware or software installation.

ChromaCode's primary customer segment is clinical and molecular diagnostic laboratories performing oncology and genomic testing, with secondary customers in pharmaceutical companies seeking customizable assays for companion diagnostics and clinical trial support. The company generates revenue through the sale of proprietary HDPCR reagent kits combined with subscriptions to ChromaCode Cloud software, sold direct via a sales-led motion. The instrument-agnostic architecture allows adoption on existing real-time and digital PCR instruments, enabling decentralized distribution into community labs for repeat-testing applications such as treatment monitoring and transplant rejection surveillance. Named reference customers include the University of Minnesota Medical School, and the company has cited market opportunities of 1.9M US patients annually for tumor profiling, 3.3M-6.7M for MRD, and 1.6M US tests for transplant rejection monitoring.

The company has raised approximately $97.8M across disclosed funding rounds since 2017, including a $37.97M round in 2022 and a strategic corporate investment from Global Brain's Shimadzu Future Innovation Fund in June 2023. ChromaCode operates with 51-100 employees and is pursuing product extensions into Minimal Residual Disease (MRD) testing and disease monitoring, both currently labeled as in development on the company's website.

ChromaCode firmographics

Firmographics
Name
ChromaCode
Legal name
ChromaCode, Inc.
Website
https://chromacode.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
ChromaCode is a molecular diagnostics company that develops HDPCR™ multiplexing chemistry and ChromaCode Cloud™ SaaS, enabling clinical laboratories and pharmaceutical companies to perform NGS-quality multi-analyte oncology and genomic testing on existing PCR instruments.
Ownership category
akta.pro rank

ChromaCode industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Molecular diagnostics
  • PCR multiplexing
  • Clinical bioinformatics
  • Oncology genomics
  • Reagent kits

Where ChromaCode is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ChromaCode business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. HDPCR Reagent Kits: Sale of proprietary HDPCR reagent kits for molecular profiling applications. The company enables ≥80% margins for lab partners through low cost of goods sold and higher throughput compared to conventional dPCR.
  2. ChromaCode Cloud Software Subscription: Cloud-based software-as-a-service for data analysis and interpretation. ChromaCode Cloud provides automated decoding and comprehensive results with secure, HIPAA and HITRUST compliant data handling. Account setup in minutes with no installation required.

Pricing tiers

ModelBillingPrice
OtherMonthlyReagent kits and ChromaCode Cloud software - contact for pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

ChromaCode product offering

Product offering

Core offering

ChromaCode sells proprietary HDPCR™ (High-Definition PCR) reagent kits paired with the ChromaCode Cloud™ SaaS software platform to clinical laboratories and pharmaceutical companies. The HDPCR chemistry enables high-level multiplexing of DNA and RNA biomarkers using standard TaqMan probes and commercial PCR instruments, while ChromaCode Cloud automatically decodes the PCR signal data to deliver comprehensive multi-analyte results in minutes without requiring hardware or software installation. The integrated platform supports tumor profiling, minimal residual disease (MRD) testing, and disease monitoring applications.

Product overview

ChromaCode offers a genomics multiplexing platform consisting of two integrated components: HDPCR™ (High-Definition PCR) technology and ChromaCode Cloud™ software. HDPCR is the core chemistry platform that enables high-multiplexing PCR testing using standard instruments, TaqMan probes, and commercial enzymes. ChromaCode Cloud is the companion SaaS platform that automates data analysis, providing signal decoding and target identification for results generation. The platform is instrument-agnostic and supports standard real-time and digital PCR instrument output files.

Differentiator

Problem solved

Functional benefit

Products and services

  • HDPCR™ (High-Definition PCR) Reagent Kits Proprietary multiplexing PCR reagent kits that use amplitude modulation and multi-spectral encoding with standard TaqMan probes and commercial enzymes to enable >4X multiplexing compared to conventional digital PCR. Sold to clinical laboratories and pharmaceutical companies for tumor profiling, MRD testing, and disease monitoring applications.
  • ChromaCode Cloud™ Cloud-based SaaS platform that automates decoding of PCR signal data from HDPCR assays, providing comprehensive multi-analyte results in minutes without requiring hardware or software installation. Supports most standard real-time and digital PCR instrument output files and is HIPAA, HITRUST, ISO 13485, and GDPR compliant. Sold to clinical laboratories alongside HDPCR reagent kits.

Quantifiable outcome

  • >4X multiplexing vs conventional dPCR
  • +4 more outcomes

Companies that use ChromaCode

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

ChromaCode technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature4 records

ChromaCode partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

ChromaCode competitors and assessment

Company assessment

Direct peers

  • Bio-Rad Laboratories: Bio-Rad's QX200 Droplet Digital PCR and related real-time/digital PCR reagent lines compete directly with ChromaCode's HDPCR multiplexing chemistry for clinical lab oncology and genomics applications. Both companies target the same workflow gap between PCR and NGS.
  • Natera: Natera's Signatera tumor-informed MRD test competes head-on with ChromaCode's HDPCR MRD pipeline, both targeting the same 3.3M+ US patient MRD opportunity. They compete for the same oncology monitoring recurring-revenue economics ChromaCode is positioning HDPCR to disrupt at lower cost.
  • Adaptive Biotechnologies: Adaptive's clonoSEQ is the dominant NGS-based MRD test for hematologic malignancies, competing directly with ChromaCode's HDPCR MRD development pipeline. Both target the same cancer monitoring use case where ChromaCode claims comparable NGS sensitivity at lower cost.
  • Guardant Health: Guardant's liquid biopsy and tumor profiling products (Guardant360, Reveal MRD) compete in the same oncology biomarker panel market that HDPCR targets, though using NGS-based approaches. They overlap on customer base (clinical labs and oncologists) and use case (comprehensive genomic profiling).
  • Personalis: Personalis's NeXT Personal and related tumor profiling/MRD offerings compete directly with ChromaCode's HDPCR oncology menu. Both target biopharma companion Dx and clinical oncology customers seeking comprehensive genomic profiling and minimal residual disease monitoring.
  • Standard BioTools (formerly Fluidigm): Standard BioTools' Biomark HD and Juno systems, plus Advanta dPCR assays, are direct multiplexing PCR competitors to HDPCR. They serve the same oncology and immunology research and clinical lab customers seeking high-content PCR panels.

Broad incumbents

  • QIAGEN: QIAGEN is a broad molecular diagnostics incumbent offering sample-prep to interpretation workflows used by the same clinical lab customers ChromaCode serves. Its QIAcuity digital PCR platform and oncology sample-to-insight portfolio directly overlap HDPCR's positioning as a PCR-to-NGS bridging solution.
  • NeoGenomics: NeoGenomics operates clinical oncology laboratories offering comprehensive tumor profiling and MRD testing, overlapping ChromaCode's end-customer base and use cases. While a service provider rather than a platform vendor, it represents the incumbent lab workflow ChromaCode's decentralized kit model aims to displace.
  • Exact Sciences: Exact Sciences (Cologuard, Oncotype, Previon) operates in molecular diagnostics with growing oncology MRD and tumor profiling ambitions that overlap ChromaCode's stated roadmap. It represents a broad incumbent with the commercial scale and reimbursement leverage ChromaCode would need to compete with at full scale.

Emerging players

  • Stilla Technologies: Stilla's naica digital PCR system is an emerging multiplexing dPCR platform competing in the same oncology and liquid biopsy use cases as HDPCR. Both companies target labs seeking higher multiplexing than conventional dPCR at lower complexity than NGS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ChromaCode social profiles

Digital presence

ChromaCode compliance and trust

Trust signal

Compliance4 records

ChromaCode financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChromaCode leadership team

Management profile

Number of profiles

Profiles6 records

ChromaCode funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChromaCode M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChromaCode

What does ChromaCode do?

ChromaCode sells proprietary HDPCR™ (High-Definition PCR) reagent kits paired with the ChromaCode Cloud™ SaaS software platform to clinical laboratories and pharmaceutical companies. The HDPCR chemistry enables high-level multiplexing of DNA and RNA biomarkers using standard TaqMan probes and commercial PCR instruments, while ChromaCode Cloud automatically decodes the PCR signal data to deliver comprehensive multi-analyte results in minutes without requiring hardware or software installation. The integrated platform supports tumor profiling, minimal residual disease (MRD) testing, and disease monitoring applications.

Is ChromaCode a public or private company?

ChromaCode is a private company. It is classified as venture growth investor backed and is currently operating.

When was ChromaCode founded?

ChromaCode was founded in 2012. It employs 11 to 50 people.

Where is ChromaCode based?

ChromaCode is headquartered in Carlsbad, United States, in the North America region.

How does ChromaCode make money?

Two revenue lines are on record. HDPCR Reagent Kits are the primary driver. The others are chromaCode Cloud Software Subscription.

Who are ChromaCode's main competitors?

Direct peers on record are Bio-Rad Laboratories, Natera, Adaptive Biotechnologies, Guardant Health, Personalis and Standard BioTools (formerly Fluidigm). Broad incumbents are QIAGEN, NeoGenomics and Exact Sciences. Stilla Technologies is listed as an emerging player.

Does ChromaCode have an API?

No public API is recorded for ChromaCode.

What industry is ChromaCode in?

ChromaCode's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireChromaCode To Show New Data In Oncology and Blood Based Monitoring at the Association for Molecular Pathology 2023 Annual Meeting and ExpoChromaCode, Inc. will present new data through a corporate workshop and two scientific abstracts at the Association for Molecular Pathology (AMP) 2023 Annual Meeting in Salt Lake City, Utah from November 14-18, 2023. The presentations will showcase the company's HDPCR multiplexing technology and ChromaCode Cloud software for oncology applications and blood-based monitoring, including solid and hematologic malignancies, transplant rejection testing, and minimal residual disease monitoring. The company will also present poster abstracts on rapid digital PCR testing for non-small cell lung cancer variants and molecular biomarker detection in acute myeloid leukemia samples.FinSMEsChromaCode Receives Strategic Investment From Shimadzu Future Innovation FundChromaCode, a genomics platform company based in Carlsbad, California, has received a strategic investment from the Shimadzu Future Innovation Fund. The undisclosed funding will support the continued development of ChromaCode's HDPCR technology for diagnostic tools addressing clinical needs in disease detection and monitoring.Global BrainGlobal Brain has invested in ChromaCode Inc., a genomics multiplexing platform company developing accessible and affordable genome testingGlobal Brain has invested in ChromaCode Inc. through its Shimadzu Future Innovation Fund L.P. to support the development of accessible and affordable genome testing solutions. The investment aims to help ChromaCode expand its High Definition PCR technology, with Global Brain planning to cooperate with Shimadzu Corporation to drive business growth.PR NewswireChromaCode Showcases HDPCR Oncology Data on QuantStudio Absolute Q dPCR System at the AMP 2022 Annual MeetingChromaCode announced it will present HDPCR oncology data developed in collaboration with Thermo Fisher Scientific at the AMP 2022 Annual Meeting in Phoenix, Arizona, demonstrating how its HDPCR technology expands multiplexing capabilities on the QuantStudio Absolute Q dPCR System. The prototype oncology assay can detect 14 DNA variants and 15 RNA fusion variants relevant in non-small cell lung cancer samples using just one slide of FFPE tissue, achieving results in 24 hours at a fraction of the cost of NGS testing. The companies plan to launch this as ChromaCode's first Research Use Only (RUO) oncology assay, with the presentation scheduled for November 3, 2022.SecSEC FORM DChromaCode, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b), with total offering amounts reaching $50,685,025. The filing indicates that $27,967,512 had been sold to 15 investors as of February 28, 2022. This regulatory submission discloses the company's capital raising activities in the biotechnology sector.SecSEC FORM DChromaCode, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates a total offering amount of $42,967,511, with $37,967,513 already sold to 16 investors as of February 28, 2022. The company is based in Carlsbad, California, and the offering involves equity securities.BioSpaceChromaCode Adds Industry Leaders, Pat Balthrop and Kevin O’Boyle, to Board of DirectorsChromaCode announced that Patrick Balthrop and Kevin O'Boyle joined its Board of Directors. Balthrop is former Luminex CEO and chairman of Agendia and Discovery Life Sciences; O'Boyle was chairman of GenMark Diagnostics. The company said their expertise will support expansion in oncology, reproductive health, and infectious disease.ForbesChromaCode Pioneering Advancements In BioinformaticsChromaCode, a molecular diagnostics company, deploys inexpensive reagent kits and software on existing PCR systems, with cloud-based computation. The company has shipped 4 million COVID tests and raised $50 million in venture funding. It plans to expand beyond COVID testing into oncology and other diagnostic markets.PR NewswireChromaCode Selected as a Winner of $6M XPRIZE Rapid COVID Testing CompetitionChromaCode, Inc. announced it was selected as one of five winners in the XPRIZE Rapid COVID Testing competition, which aimed to increase COVID-19 testing capabilities 100 times past the current standard,筛选 from an original pool of approximately 700 applicants. The company's HDPCR platform uses proprietary digital signal processing, enhanced PCR reagents, and cloud-based analytics to expand testing capacity fivefold while reducing costs. ChromaCode hosts over three million COVID-19 tests on its ChromaCode Cloud platform, powered by Amazon Web Services, and plans to use a portion of the prize to expand its test menu for emerging variants and subsidize testing for schools and businesses.PR NewswireChromaCode Core HDPCR Technology Reaches a New MilestoneChromaCode demonstrated the scalability of its HDPCR technology to detect 20 biomarkers in a single well using conventional qPCR instruments, achieving a fivefold increase in analytical capacity over standard multiplex PCR. The findings were published in the journal Analytical Chemistry through a collaboration with Professor Scott Fraser at the University of Southern California. The company states this advancement enables scalable, affordable enhanced multiplex diagnostic assays to guide precision medicine at economical costs on existing instruments.